MOORESTOWN, N.J.–(BUSINESS WIRE)–Tabula Rasa HealthCare, Inc. Chairman and Chief Executive Officer, Calvin H. Knowlton, BSc Pharm, MDiv, PhD, announced today the appointment of Jacques Turgeon, B.Pharm., Ph.D., to the company’s newly created position of Chief Scientific Officer. Tabula Rasa HealthCare offers medication risk mitigation and risk adjustment services for at-risk health plans, health systems, hospitals, skilled rehabilitation, long-term care, and other healthcare entities.
“We believe that by limiting drug-drug interaction, healthcare providers and patients will recognize both healthcare and financial savings”
Dr. Turgeon joins Tabula Rasa HealthCare with a long and successful track record of management and scientific achievements from both academia and the private sector. Until recently, Dr. Turgeon was the CEO of the Centre hospitalier de l’Université de Montréal, a leading francophone university hospital in the province of Quebec. From 2007-2014, Dr. Turgeon served as the director of the Research Center of the Centre hospitalier de l’Université de Montréal, and from 2000 to 2005, he was Dean of the Faculty of Pharmacy at the Université de Montréal. Currently, he is a full professor at the Université in drug metabolism, pharmacokinetics and pharmacogenomics. Previously, Dr. Turgeon served as Senior Director of the pharmacokinetics department at Phoenix International Life Sciences in Montréal.
Dr. Turgeon is recognized internationally for his work on Cytochrome P450s (CYP450) and mechanisms of drug-drug interactions. CYP450 is a family of enzymes important to patients of all ages, and especially in elderly patients where CYP450 plays a key role in the proper dosage of medications to avoid undesirable side effects. Dr. Turgeon’s interest in applying this knowledge led to his creation and development of InterMed-Rx, a drug-drug interaction analysis software licensed by Tabula Rasa HealthCare and currently in use in major hospitals and pharmacies in Quebec. Recent studies have demonstrated that up to 28% of emergency room visits were drug-related. “We believe that by limiting drug-drug interaction, healthcare providers and patients will recognize both healthcare and financial savings,” said Turgeon.
According to CEO Knowlton, Dr. Turgeon will play an important role in organizing and supervising efforts for patient’s pharmacotherapy optimization. “His extensive experience and knowledge in managing healthcare organizations and developing cutting edge research tools will enhance our capabilities and help grow our company and product offerings. We will be able to provide better clinical services to healthcare organizations and at-risk healthcare sectors,” stated Knowlton.Share this: